Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Pancrelipase Delayed Release in Infants and Children with CF-related PEI
NCT00775528Phase 3Completed
- Sponsor
- Solvay
- Start
- Apr 2009
- Primary completion
- Jun 2009
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pancrelipase in pancreatic exocrine insufficiency (EPI), sponsored by Solvay. Primary endpoint: Number of Patients With at Least One Treatment Emergent Adverse Event at 10 days. Started Apr 2009; status: completed.
02
Drugs
pancrelipase
03
Conditions
pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT00775528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00775528.